# Virus DNX2401 and Temozolomide in Recurrent Glioblastoma

Source: https://onco.cc/trials/nct01956734/  
OnCo record `nct01956734` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of DNX-2401 run by Clinica Universidad de Navarra, Universidad de Navarra, completed.

## Summary

Virus DNX2401 and Temozolomide in Recurrent Glioblastoma is a phase 1 interventional study registered as NCT01956734 by Clinica Universidad de Navarra, Universidad de Navarra, with 31 participants enrolled, started 2013-09. Conditions recorded: Glioblastoma Multiforme and Recurrent Tumor. Interventions recorded: DNX2401 and Temozolomide.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT01956734
- Phase: 1
- Setting: Phase I Trial of Combination of DNX-2401 (Formerly Named Delta-24-RGD) Oncolytic Adenovirus With a Short Course of Temozolomide for Treatment of Glioblastoma at First Recurrent
- Sponsor: Clinica Universidad de Navarra, Universidad de Navarra
- Enrolled: 31

## Sources

- ClinicalTrials.gov NCT01956734: https://clinicaltrials.gov/study/NCT01956734

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [DNX-2401](https://onco.cc/drugs/dnx-2401/)
- companies: [DNAtrix](https://onco.cc/companies/dnatrix/)

---
JSON: https://onco.cc/api/v1/entities/nct01956734.json